EP2049105A4 - Thérapie photodynamique antimicrobienne - Google Patents

Thérapie photodynamique antimicrobienne Download PDF

Info

Publication number
EP2049105A4
EP2049105A4 EP07797049.9A EP07797049A EP2049105A4 EP 2049105 A4 EP2049105 A4 EP 2049105A4 EP 07797049 A EP07797049 A EP 07797049A EP 2049105 A4 EP2049105 A4 EP 2049105A4
Authority
EP
European Patent Office
Prior art keywords
photodynamic therapy
microbial
microbial photodynamic
therapy
photodynamic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP07797049.9A
Other languages
German (de)
English (en)
Other versions
EP2049105A2 (fr
Inventor
Nikolay E. Nifantiev
Burkhard Gitter
Dmitri V. Yashunsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biolitec AG
Original Assignee
Biolitec AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/880,974 external-priority patent/US20090030257A1/en
Application filed by Biolitec AG filed Critical Biolitec AG
Publication of EP2049105A2 publication Critical patent/EP2049105A2/fr
Publication of EP2049105A4 publication Critical patent/EP2049105A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Radiation-Therapy Devices (AREA)
  • Apparatus For Disinfection Or Sterilisation (AREA)
EP07797049.9A 2006-07-27 2007-07-27 Thérapie photodynamique antimicrobienne Pending EP2049105A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83383606P 2006-07-27 2006-07-27
US11/880,974 US20090030257A1 (en) 2007-07-25 2007-07-25 Anti-microbial photodynamic therapy
PCT/US2007/016951 WO2009014524A2 (fr) 2006-07-27 2007-07-27 Thérapie photodynamique antimicrobienne

Publications (2)

Publication Number Publication Date
EP2049105A2 EP2049105A2 (fr) 2009-04-22
EP2049105A4 true EP2049105A4 (fr) 2022-03-30

Family

ID=40282008

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07797049.9A Pending EP2049105A4 (fr) 2006-07-27 2007-07-27 Thérapie photodynamique antimicrobienne

Country Status (4)

Country Link
EP (1) EP2049105A4 (fr)
BR (1) BRPI0714667A8 (fr)
MX (1) MX2009001074A (fr)
WO (1) WO2009014524A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020326320A1 (en) * 2019-08-02 2022-03-10 Koite Health Oy Method of enhancing the antimicrobial action of systemically administered antibiotics
CN114053406B (zh) * 2021-11-23 2022-12-09 华中科技大学 一种多功能光热纳米杀菌材料及制备与应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6462070B1 (en) * 1997-03-06 2002-10-08 The General Hospital Corporation Photosensitizer conjugates for pathogen targeting
US20040186087A1 (en) * 2003-03-20 2004-09-23 Ceramoptec Industries, Inc. Siderophore conjugates of photoactive dyes for photodynamic therapy
US20050281777A1 (en) * 2004-06-18 2005-12-22 Ceramoptec Industries, Inc. Photo-triggered release of active substances from dendrimer-photosensitizer complexes

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030215421A1 (en) * 1999-07-21 2003-11-20 Mcdonald John R. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
EP1389090A2 (fr) * 2001-04-26 2004-02-18 Board of Regents, The University of Texas System Compositions d'imagerie diagnostique, leurs methodes de synthese et utilisation
US20030176326A1 (en) * 2002-03-15 2003-09-18 Ceramoptec Industries Inc. Photosensitzers for photodynamic therapy of microbial infections
US20050153371A1 (en) * 2004-01-07 2005-07-14 Ambit Biosciences Corporation Conjugated small molecules

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6462070B1 (en) * 1997-03-06 2002-10-08 The General Hospital Corporation Photosensitizer conjugates for pathogen targeting
US20040186087A1 (en) * 2003-03-20 2004-09-23 Ceramoptec Industries, Inc. Siderophore conjugates of photoactive dyes for photodynamic therapy
US20050281777A1 (en) * 2004-06-18 2005-12-22 Ceramoptec Industries, Inc. Photo-triggered release of active substances from dendrimer-photosensitizer complexes

Also Published As

Publication number Publication date
BRPI0714667A8 (pt) 2016-10-18
WO2009014524A3 (fr) 2020-10-15
WO2009014524A2 (fr) 2009-01-29
EP2049105A2 (fr) 2009-04-22
MX2009001074A (es) 2009-06-05
BRPI0714667A2 (pt) 2013-08-06

Similar Documents

Publication Publication Date Title
HK1219911A1 (zh) 眼放射外科
EP1989185B8 (fr) Composes therapeutiques
IL196559A0 (en) Combination therapy
EP2960233B8 (fr) Nouveaux agents thérapeutiques
ZA200807934B (en) Cancer treatments
HK1205935A1 (en) Non-lithotripsic kidney-stone therapy
EP2073891A4 (fr) Stimulateur cardiaque
IL196556A0 (en) Combination therapy
EP2054061A4 (fr) Thérapie par combinaison
AU2008263581A8 (en) Well treatment
EP2010570B8 (fr) Therapie vers cathepsin s
ZA200902203B (en) Combination therapy
EP2049105A4 (fr) Thérapie photodynamique antimicrobienne
GB0606660D0 (en) Targeted Therapy
AU2006902723A0 (en) Therapeutic treatment
AU2007903369A0 (en) Therapeutic Agents
AU2006901059A0 (en) Therapeutic Agents
AU2006905623A0 (en) Treatment
AU2006100583A4 (en) Treatment Planning Made Easy
AU2008903284A0 (en) Combination therapy
AU2006902304A0 (en) Eye treatment
AU2008902703A0 (en) Therapeutic agents
AU2008902139A0 (en) HLST Therapy
GB0603430D0 (en) Therapy
GB0615039D0 (en) Therapy

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BIOLITEC PHARMA IP & INVESTMENT LTD.

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BIOLITEC UNTERNEHMENSBETEILIGUNGS II AG

R17D Deferred search report published (corrected)

Effective date: 20201015

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210415

RBV Designated contracting states (corrected)

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

A4 Supplementary search report drawn up and despatched

Effective date: 20220225

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 31/04 20060101ALI20220221BHEP

Ipc: A61K 31/407 20060101ALI20220221BHEP

Ipc: A61K 47/64 20170101ALI20220221BHEP

Ipc: A61K 41/00 20060101AFI20220221BHEP